.

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,422,123

« Back to Dashboard

Summary for Patent: 5,422,123

Title: Tablets with controlled-rate release of active substances
Abstract:Tablets with zero order controlled-rate of release of the active substances, consisting of a core of defined geometrical form containing the active substance, polymer substances which swell on contact with aqueous liquids and polymer substances with gelling properties, and a support applied to said core to partly cover its surface, the support consisting of polymer substances which are slowly soluble and/or slowly gellable in aqueous liquids, plasticizing substances, and possibly substances with an adjuvant function.
Inventor(s): Conte; Ubaldo (Busto Arsizio, IT), La Manna; Aldo (Pavia, IT), Colombo; Paolo (Pavia, IT)
Assignee: Jagotec AG (Hergiswil, CH)
Application Number:08/123,982
Patent Claim Types:
see list of patent claims
Composition; Process; Dosage form;
Patent PDF download available with subscription

No matches for this query

Foreign Priority and PCT Information for Patent: 5,422,123

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Italy22694/89Dec 14, 1989

International Patent Family for Patent: 5,422,123

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria135906<disabled in preview>
Canada2031393<disabled in preview>
Germany69026215<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

`abc